Hungarian Drug Prices, Health Debts And Generics

18 December 1995

In Hungary, Zsuzsa Matejka, the chief pharmacist at the National Health Insurance Office, has said that the prices of medicines there will rise by an average of 14% some time around January 15, 1996. Prices of Hungarian-made medicines are expected to increase more than prices of imported products, according to MTI Econews.

Drug subsidies granted by the NIO will increase in line with price adjustments. Spending on health care in Hungary in the first four months of 1996 is expected to be 5% higher than the average monthly amount in 1995, the report adds.

In the first 10 months of 1995, hospitals had accumulated debts of 8 billion forint ($58 million). 199 billion forint was expected to be spent on medical treatment and preventive medicine throughout the health service in 1995, rising to 215 billion forint in 1996.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight